Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2021

View Archived Issues

aTyr Pharma initiates new discovery programs from its tRNA synthetase platform

Incyte begins phase II study with retifanlimab in advanced or metastatic endometrial cancer

New phase I/II study evaluates hLB-001 in pediatric patients with severe methylmalonic acidemia

Promising preclinical data for SIG-005 encapsulated nonviral cell-based therapy for MPS

Phase III studies show superiority of topical tirbanibulin to vehicle in actinic keratosis

Nonhuman primate models of COVID-19 through airborne exposure to SARS-CoV-2

A humanized mouse model of Pneumocystis pneumonia to better understand the human immune response

Tocilizumab in addition to steroids shows benefit in patients hospitalized with COVID-19

Reata Pharmaceuticals identifies new nitric oxide production inhibitors

Heat shock or hypoxia triggers amyloids, translation in nucleus

FDA approves Cosela for myeloprotection in patients with extensive-stage SCLC receiving chemotherapy

TMEM16A calcium-activated chloride channel as a novel therapeutic target against HRSV

REG3A unveiled as a risk marker for gastrointestinal chronic GvHD

Roche presents phase III data for faricimab in patients with DME and nAMD

Phase I/II data presented for Trappsol Cyclo in patients with NPC1

Panzyga approved in U.S. for chronic inflammatory demyelinating polyneuropathy

RBD-SpyVLP COVID-19 vaccine shows promise in preclinical studies

Phase II study evaluates E-52862 in early treatment of outpatients with mild COVID-19 symptoms

New phase II trial investigates ChAdOx1 nCoV-19 coronavirus vaccine in children

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...